• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Funds

Archimed closes MED II on EUR 3.5bn

  • Rachel Lewis
  • 05 June 2023
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Specialist healthcare sponsor Archimed has held a final close for its second mid-cap fund on EUR 3.5bn, well above the fund's EUR 2bn target in a difficult fundraising environment.

The French GP set MED II's initial target at EUR 2bn, after launching fundraising in January 2022, but raised this limit twice to accommodate investors and "cope with rich deal flow", it said in a statement. 

Main commitments to the fund amount to EUR 3bn, with the remainder committed to a side vehicle for co-investments. 

MED Platform II

  • Target:

    EUR 2bn

  • Launched:

    January 2022

  • Closed on:

    EUR 3.5bn

  • Focus:

    Mid-cap healthcare

  • Fund manager:

    ArchiMed

The fund is EUR 2bn larger than its predecessor, MED I, which comprised EUR 1bn for the main fund and EUR 500m for a side vehicle. 

The sponsor has seen five high multiple exits in the last 18 months, with all recording returns of 3x-6x, it said - although it has failed to make some anticipated exits, with UK-based occupational health group Vita Health stalled and Deallus missing in action following reporting from Mergermarket on both processes in 2022. 

Investors
MED II saw a re-up of almost 100% and also attracted new investors globally among institutional investors and family offices, Archimed said. Around 40% of its investors are from Europe, 30% from North America and 30% from other regions, especially Asia. 

Investments
MED II will target 14 investments versus the seven that MED I invested in, with a focus on mid-cap healthcare buyouts. 

When the fund launched, Archimed founding partner Denis Ribon tod Unquote that it would stick to its portfolio mix of around 20-30% for biopharma, 20-30% for medtech, 15-20% for consumer health and the same again for life sciences tools, plus 10-15% for diagnostics and healthcare IT.

The fund has already deployed almost EUR 1bn of its capital, via the USD 1.2bn take private of Nasdaq-listed medical devices company Natus in 2Q23, as well as the buyout of German plasmids developer Plasmid Factory. 

People
Archimed
- Denis Ribon (chairman, founding partner).

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Funds
  • Buyout
  • Healthcare
  • France
  • DACH
  • UK / Ireland
  • Benelux
  • Archimed
  • France

More on Funds

Fund closes in US dollars
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • Funds
  • 05 September 2023
Bettina Curtze of Redalpine
Redalpine expands leadership team amid CHF 1bn-plus fundraise

Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO

  • Venture
  • 31 August 2023
Andris K. Berzins of Change Ventures
Change Ventures aims to hold final close for EUR 20m third fund by mid-2024

Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds

  • Funds
  • 31 August 2023
Fund launches in euros
Iron Wolf Capital targets EUR 70m for second vehicle

Baltic investor anticipates early 2024 launch and will focus on early-stage AI and deeptech startups

  • Funds
  • 30 August 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013